Is Ionis Pharmaceuticals Stock a Good Investment?

Ionis Pharmaceuticals Investment Advice

  IONS
To provide specific investment advice or recommendations on Ionis Pharmaceuticals stock, we recommend investors consider the following general factors when evaluating Ionis Pharmaceuticals. This will help you to make an informed decision on whether to include Ionis Pharmaceuticals in one of your diversified portfolios:
  • Examine Ionis Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Ionis Pharmaceuticals' leadership team and their track record. Good management can help Ionis Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact Ionis Pharmaceuticals' business and its evolving consumer preferences.
  • Compare Ionis Pharmaceuticals' performance and market position to its competitors. Analyze how Ionis Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
  • Check if Ionis Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Ionis Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ionis Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ionis Pharmaceuticals is a good investment.
 
Sell
 
Buy
Strong Hold
Ionis Pharmaceuticals investment recommendation module can be used to check and cross-verify current trade recommendations provided by analysts evaluating the entity's potential to grow using all of fundamental, technical, data market data available at the time. To make sure Ionis Pharmaceuticals is not overpriced, please check out all Ionis Pharmaceuticals fundamentals, including its price to sales, short ratio, net asset, as well as the relationship between the cash per share and market capitalization . Given that Ionis Pharmaceuticals has a price to earning of 101.16 X, we strongly advise you to confirm Ionis Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Market Performance

Very WeakDetails

Volatility

Very steadyDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Barely shadows the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine Ionis Pharmaceuticals Stock

Researching Ionis Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 101.16. Ionis Pharmaceuticals recorded a loss per share of 2.56. The entity had not issued any dividends in recent years.
To determine if Ionis Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ionis Pharmaceuticals' research are outlined below:
Ionis Pharmaceuticals generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 787.65 M. Net Loss for the year was (366.29 M) with loss before overhead, payroll, taxes, and interest of (257.87 M).
Ionis Pharmaceuticals currently holds about 2.04 B in cash with (307.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36.
Ionis Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 99.0% of the company shares are owned by institutional investors
Latest headline from seekingalpha.com: Ionis experimental drug meets key goal in familial chylomicronemia study
Ionis Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ionis Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ionis Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Ionis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ionis Pharmaceuticals' investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-02-27
2017-12-310.010.020.01100 
2013-05-07
2013-03-31-0.02-0.03-0.0150 
2009-08-06
2009-06-30-0.02-0.03-0.0150 
2018-05-04
2018-03-31-0.03-0.010.0266 
2017-05-09
2017-03-310.050.03-0.0240 
2016-11-09
2016-09-300.080.06-0.0225 
2012-02-29
2011-12-31-0.18-0.2-0.0211 
2014-11-07
2014-09-30-0.2-0.23-0.0315 

Know Ionis Pharmaceuticals' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Ionis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ionis Pharmaceuticals backward and forwards among themselves. Ionis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ionis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Tweedy, Browne Co Llc2023-12-31
3.5 M
Macquarie Group Ltd2023-12-31
3.1 M
Geode Capital Management, Llc2023-12-31
2.3 M
Orbimed Advisors, Llc2023-12-31
2.1 M
Ark Investment Management Llc2023-12-31
1.9 M
Farallon Capital Management, L.l.c.2023-12-31
1.6 M
Adage Capital Partners Gp Llc2023-12-31
1.4 M
Charles Schwab Investment Management Inc2023-12-31
1.3 M
Deep Track Capital, Lp2023-12-31
1.2 M
Fmr Inc2023-12-31
21.5 M
Vanguard Group Inc2023-12-31
14.2 M
Note, although Ionis Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ionis Pharmaceuticals' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.08 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ionis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ionis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Market Cap

6.85 Billion

Ionis Pharmaceuticals' profitablity analysis

Ionis Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Ionis Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Ionis Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ionis Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ionis Pharmaceuticals' profitability requires more research than a typical breakdown of Ionis Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.12)(0.13)
Return On Capital Employed(0.14)(0.15)
Return On Assets(0.12)(0.13)
Return On Equity(0.95)(0.99)
The company has Profit Margin (PM) of (0.46) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05.
Determining Ionis Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Ionis Pharmaceuticals is a good buy. For example, gross profit margin measures Ionis Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ionis Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Ionis Pharmaceuticals' official financial statements usually reflect Ionis Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Ionis Pharmaceuticals. For example, before you start analyzing numbers published by Ionis accountants, it's critical to develop an understanding of what Ionis Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Ionis Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ionis Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Ionis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ionis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Ionis Pharmaceuticals' management manipulating its earnings.

Evaluate Ionis Pharmaceuticals' management efficiency

Ionis Pharmaceuticals has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7634) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2024. Return On Capital Employed is likely to drop to -0.15 in 2024. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 365.6 M in 2024, whereas Intangible Assets are likely to drop slightly above 24.2 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 2.70  2.12 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 2.70  1.97 
Enterprise Value Over EBITDA(25.70)(26.99)
Price Book Value Ratio 18.73  17.80 
Enterprise Value Multiple(25.70)(26.99)
Price Fair Value 18.73  17.80 
Enterprise Value7.5 B7.8 B
The analysis of Ionis Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Ionis Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Ionis Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.402

Basic technical analysis of Ionis Stock

As of the 16th of April 2024, Ionis Pharmaceuticals retains the Market Risk Adjusted Performance of (16.64), standard deviation of 1.91, and Risk Adjusted Performance of (0.10). Ionis Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate thirteen technical drivers for Ionis Pharmaceuticals, which can be compared to its competitors. Please check out Ionis Pharmaceuticals variance and skewness to decide if Ionis Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 41.74 per share. Given that Ionis Pharmaceuticals has information ratio of (0.21), we strongly advise you to confirm Ionis Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.

Ionis Pharmaceuticals' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ionis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ionis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ionis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ionis Pharmaceuticals' Outstanding Corporate Bonds

Ionis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ionis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ionis bonds can be classified according to their maturity, which is the date when Ionis Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Ionis Pharmaceuticals' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Ionis Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Ionis Pharmaceuticals' intraday indicators

Ionis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ionis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ionis Pharmaceuticals Corporate Filings

8K
21st of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
16th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
13th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
ASR
24th of November 2023
Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC)
ViewVerify
Ionis Pharmaceuticals time-series forecasting models is one of many Ionis Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ionis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Ionis Stock media impact

Far too much social signal, news, headlines, and media speculation about Ionis Pharmaceuticals that are available to investors today. That information is available publicly through Ionis media outlets and privately through word of mouth or via Ionis internal channels. However, regardless of the origin, that massive amount of Ionis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ionis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ionis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ionis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ionis Pharmaceuticals alpha.

Ionis Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Ionis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ionis Pharmaceuticals Historical Investor Sentiment

Investor biases related to Ionis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ionis. The trend in average sentiment can be used to explain how an investor holding Ionis can time the market purely based on public headlines and social activities around Ionis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ionis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ionis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ionis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Ionis Pharmaceuticals.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Ionis Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Ionis Pharmaceuticals Corporate Directors

Ionis Pharmaceuticals corporate directors refer to members of an Ionis Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Ionis Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Ionis Pharmaceuticals' board members must vote for the resolution. The Ionis Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Joseph KleinIndependent DirectorProfile
Michael HaydenDirectorProfile
Spencer BerthelsenIndependent DirectorProfile
Frederick MutoIndependent DirectorProfile

How to buy Ionis Stock?

To provide specific investment advice or recommendations on Ionis Pharmaceuticals stock, we recommend investors consider the following general factors when evaluating Ionis Pharmaceuticals. This will help you to make an informed decision on whether to include Ionis Pharmaceuticals in one of your diversified portfolios:
  • Examine Ionis Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Ionis Pharmaceuticals' leadership team and their track record. Good management can help Ionis Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact Ionis Pharmaceuticals' business and its evolving consumer preferences.
  • Compare Ionis Pharmaceuticals' performance and market position to its competitors. Analyze how Ionis Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
  • Check if Ionis Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Ionis Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ionis Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ionis Pharmaceuticals is a good investment.

Already Invested in Ionis Pharmaceuticals?

The danger of trading Ionis Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ionis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ionis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ionis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ionis Pharmaceuticals is a strong investment it is important to analyze Ionis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ionis Pharmaceuticals' future performance. For an informed investment choice regarding Ionis Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Ionis Stock analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.44)
Earnings Share
(2.56)
Revenue Per Share
5.501
Quarterly Revenue Growth
1.136
Return On Assets
(0.08)
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ionis Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.